ADS Securities London Limited has integrated Autochartist’s comprehensive trading platform into its UK retail operations, extending the utility to its regional FX client base – the new initiative will see the assimilation of Autochartist’s market scanner capabilities into the MT4 Trading ecosystem, according to an ADS Securities statement.
The new world of online trading, fintech and marketing – register now for the Finance Magnates Tel Aviv Conference, June 29th 2016.
The latest adoption of Autochartist’s utility also helps lay the framework for a symbiotic partnership, combined with ADS Securities’ liquidity. In broader terms, the initiative also helps expand ADS Securities London’s base on the European stage, which has been one of its goals as it looks to augment its overall retail clientele. To date, it now offers a selection of instruments ranging from FX and spread betting to contract-for-difference (CFDs).
Viberate Teams Up with Blockparty to Deliver World’s First Live Event NFTGo to article >>
According to James Watson, Chief Executive Officer (CEO) of ADS Securities London, in a recent statement on the partnership: “There’s no doubting that the market for retail forex brokers in Europe is a congested one, so we are looking to differentiate ourselves with a focus on the very best technology.”
“We have already invested heavily in ultra low latency networks to ensure orders can be executed quickly, whilst out proprietary OREX Optim trading platform is further evidence of our commitment to deliver the very best functionality available,” he noted.
“We’re continually working to further develop the Autochartist product suite and we are delighted that ADS Securities has selected our technology. We believe that by being the first market scanner to be deployed within MT4, we are offering traders unparalleled convenience when it comes to highlighting potentially valuable trade setups – and allowing traders to take immediate action,” reiterated Ilan Azbel, co-founder and CEO of Autochartist in an accompanying statement.